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Bacteriophages are bacterial viruses, capable of killing even multi-drug resistant
bacterial cells. For this reason, therapeutic use of phages is considered as a possible
alternative to conventional antibiotics. However, phages are very host specific in
comparison to wide-spectrum antibiotics and thus preparation of phage-cocktails
beforehand against pathogens can be difficult. In this study, we evaluate whether
it may be possible to isolate phages on-demand from environmental reservoir. We
attempted to enrich infectious bacteriophages from sewage against nosocomial drug-
resistant bacterial strains of different medically important species in order to evaluate
the probability of discovering novel therapeutic phages. Stability and host-range were
determined for the acquired phages. Our results suggest that on-demand isolation
of phages is possible against Pseudomonas aeruginosa, Salmonella and extended
spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae. The probability of
finding suitable phages was less than 40% against vancomycin resistant Enterococcus
and Acinetobacter baumannii strains. Furthermore, isolation of new phages against
methicillin resistant Staphylococcus aureus strains was found to be very difficult.
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INTRODUCTION
Antibiotic resistance is an emerging global health crisis, resulting from the continuous use (and
misuse) of antibiotics in healthcare, farming industry, and elsewhere (Cantas et al., 2013; World
Health Organization [WHO], 2014). Phage therapy refers to the utilization of bacteriophages (or
just phages, viruses infecting bacteria) to treat bacterial diseases (Abedon et al., 2011). Given the
increasing number of drug-resistant bacterial infections, especially within hospital settings, the
exploration of alternatives to conventional antibiotics has become an important research objective
(Finch, 2011; Sommer and Dantas, 2011). Bacteriophages are very abundant (Hendrix et al., 1999)
and every bacterium is likely to have their own speciﬁc viruses that could be utilized as antibacterial
agents (Clokie et al., 2011; Flores et al., 2011; Örmälä and Jalasvuori, 2013). Historically, phages
were used therapeutically already in the early 20th century (Sulakvelidze et al., 2001). Yet, the
discovery of broadly eﬀective antibiotics led to the demise of the development of phage therapy
in western countries and only as the antibiotics are starting to fail there has been a serious attempt
to restore the old tool. However, the second coming of phage therapy faces challenges regarding
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to the strict regulatory guidelines and the development of
eﬀective therapeutic practices (Gill and Hyman, 2010; Lu and
Koeris, 2011; Keen, 2012). Yet, phage therapy can provide an
evolutionarily sustainable alternative to conventional antibiotics,
should we be able to adjust our regulations and procedures to
meet the special requirements of phage based medicine (Keen,
2012; Örmälä and Jalasvuori, 2013).
It is important to note that phages infect bacterial hosts very
selectively. Often, the narrow host-range is considered as an
advantage over traditional antibiotics since phage treatment can
focus accurately on the pathogen without harming commensal
bacterial ﬂora (Loc-Carrillo and Abedon, 2011). On the other
hand, bacteria develop resistance also to phages rapidly, and
thus the achieved antibacterial eﬀect may be transient (Hyman
and Abedon, 2010; Labrie et al., 2010). When multiple diﬀerent
phages are used simultaneously in a phage cocktail, development
of resistance is less likely (Skurnik et al., 2007; Chan et al.,
2013). However, it is challenging to obtain a set of phages that
is eﬀective against all variants of a given pathogen (Pirnay et al.,
2011; Chan et al., 2013). There can be a tradeoﬀ between the
host range and the therapeutic eﬃcacy of a cocktail for a speciﬁc
species of bacteria: when the number of phages in a cocktail
increases in an eﬀort to increase the host range of the cocktail,
the number of phages against a speciﬁc strain of bacteria may
decrease. Therefore, the host speciﬁcity of phages, while in theory
beneﬁcial, poses a practical problem when combined with the
rapidly emerging resistant phenotypes.
In principle, it is possible to acquire bacteriophages on-
demand to treat, for example, infections that are resistant to all
known antibiotics and oﬀ-the-shelf (standardized) phage-therapy
products (Keen, 2012; Örmälä and Jalasvuori, 2013). Tailoring a
therapeutic cocktail personally for each patient would allow the
cocktails to comprise phages that are eﬀective against the bacterial
strains responsible of the infection (Pirnay et al., 2011; Chan
et al., 2013). Therefore and in comparison to premade cocktails, a
personalized phage therapy does not carry a surplus of ineﬀective
phages. Indeed, there are older studies suggesting that tailored
phage treatments are several times more eﬀective compared
to standardized cocktails (Zhukov-Verezhnikov et al., 1978),
and thus eﬀective phage-therapy practices to treat constantly
changing bacterial pathogens may depend on the adjustment of
the treatment to the causative agent (Keen, 2012).
Generating a personal set of phages requires that the pathogen
is isolated and, then, eﬀective bacteriophages obtained against
it. One possible way for identifying suitable viruses is to have
a variety of bacteriophages isolated and prepared beforehand
and then the causative pathogen screened through the phage-
library (Chan et al., 2013). Alternatively, phages may be isolated
as needed from environmental reservoirs. In some cases, the latter
option may be inevitable due to the lack of infectious phages
in the premade libraries against all possible bacterial variants.
Ultimately, environment serves as the only source of practically
endless phage variety and thus exploitation of the environmental
resources forms the basis for personalized phage medicine.
While phages are known to be abundant, it is obvious that
all environments cannot contain infective phages against all
diﬀerent bacterial hosts (see e.g., Flores et al., 2011; Atanasova
et al., 2012). To the best of our knowledge, the probability of
ﬁnding therapeutically useful phages against diﬀerent resistant
pathogens on-demand has not been studied per se despite the
fact that it is likely to be the limiting factor in attempts to
update premade cocktails or to generate on-demand personalized
therapies (Chan et al., 2013). As an example, hospital acquired
wound infections have been suggested to be especially suitable
target for phage therapy as the causative agents are generally
resistant to various antibiotics (Loc-Carrillo et al., 2012). Yet,
there might be multiple diﬀerent bacterial species present in these
infections, including, e.g., Staphylococcus aureus, Enterococcus
faecium, Escherichia coli, Klebsiella pneumoniae, Pseudomonas
aeruginosa, and Acinetobacter baumannii (Agnihotri et al., 2004).
Therefore, a successful phage-based treatment can be dependent
on the practicality of being able to simultaneously and rapidly
isolate new durable phages against very diﬀerent pathogens.
In this study, we provide an evaluation of the on-
demand isolation of phages against the most common hospital
borne resistant pathogens: methicillin resistant S. aureus
(MRSA), extended spectrum beta-lactamase (ESBL) E. coli and
K. pneumoniae, multi-drug resistant (MDR) P. aeruginosa,
vancomycin resistant Enterococcus (VRE), A. baumannii and
diﬀerent Salmonella species. All aforementioned species are also
listed in CDC’s report on the top 18 drug-resistant threats to the
United States in 2013 (CDC, 2013). These bacteria commonly
cause infections of skin, lung and urinary tract, as well as
foodborne infections among others and aﬀect people all around
the world disregarding their background (CDC/FDA/NIH,
2011).
Sewage is known to be an optimal resource of phages (Lobocka
et al., 2014), thus a wastewater treatment plant in Jyväskylä,
Finland (Nenäinniemi) was used as the environmental reservoir
for phage hunt. The stability of the acquired viruses and their
cross-infectivity on other potential host strains were determined.
We demonstrate vast diﬀerences in probabilities of ﬁnding
novel phages against diﬀerent hosts by using enrichment method
for isolation. There appears to be severe constraints in isolating
phages on-demand against pathogens like MRSA. On the other
hand, it seems feasible to obtain phages against ESBL positive
E. coli and K. pneumoniae as well as P. aeruginosa.
MATERIALS AND METHODS
Bacteria Strains and Culturing
Conditions
Bacterial strains used in this study were mostly purchased
from Medix Laboratories or acquired from Turku University
Hospital (Supplementary Table S1). OneKlebsiella strain and four
Enterococccus strains were obtained from commercial culture
collections. Aside from six bacterial strains, all had caused
(antibiotic resistant) human infections and thus they represent
pathogens that could have been treated with phages. Overall,
we obtained 12 MRSA strains, 16 E. coli ESBL strains, 6
K. pneumonia (ESBL) strains, 17 P. aeruginosa MDR strains, 9
A. baumannii strains, 10 E. faecium (VRE) strains, 4 Enterococcus
faecalis (VRE) strains, and 9 diﬀerent Salmonella strains. Detailed
Frontiers in Microbiology | www.frontiersin.org 2 November 2015 | Volume 6 | Article 1271
Mattila et al. On-demand phage isolation
FIGURE 1 | Average density of infectious bacteriophage particles in the prepared stocks of each host species (large circle). Small circles indicate the
maximum and minimum values observed.
TABLE 1 | Summary of the decrease in phage titers as observed after
1-month storage at +4◦C.
Host bacterium Average decrease in titer (log10)
Acinetobacter baumannii 0.973
Enterococcus faecium/ faecalis 0.222
Escherichia coli 0.496
Klebsiella pneumoniae 0.594
Pseudomonas aeruginosa 0.437
Salmonella sp. 0.529
Staphylococcus aureus 0.491
characterization of the bacterial strains was beyond the scope of
this paper.
All bacteria were cultured in Lysogeny Broth (LB) -medium
(Sambrook et al., 1989) at +37◦C shaken 230 rpm (Enterococcus
strains were cultivated without shaking).
Isolation Protocol
The following isolation protocol with slight modiﬁcation in
individual experiments was used throughout the study. Either
unprocessed sewage samples or supernatants of turbid samples
(centrifuged 3000–6000 g in Megafuge 1.0R, Heraeus, or in
Eppendorf centrifuge 5702 R, 10–15 min at +4◦C) were used
in the enrichment steps. In cases where previous isolation
attempts had failed to yield phages, the supernatant was also
ﬁltrated through a 0.45 µm ﬁlter to remove all remaining
bacterial cells. The ﬁrst enrichment step was conducted using
20–30 ml of sewage water ﬁlled up to 30–40 ml with LB-
broth, depending on the volume of collected sewage samples.
The target bacterial strain was added (50–200 µl o/n culture
grown in LB-broth, 300 µl in case of E. faecium and E. faecalis)
to enrich (potential) phages in the sample. These enrichments
were cultivated overnight at +37◦C, shaken 230 rpm. Bacteria
from this enrichment culture were removed by centrifugation
(3000–6000 g in Megafuge 1.0R, Heraeus, or in Eppendorf
centrifuge 5702 R, 15–20 min, +4◦C) and ﬁltration (0.2 or
0.45µmﬁlter). The amount of potential phages in a 2.5ml sample
of the bacteria-free enrichment were further ampliﬁed by adding
2.5 ml of LB-broth and 50–100 µl of the target host bacterium
and were grown overnight as above. The sample from this second
enrichment step was centrifuged at 13 000 g for 15 min at room
temperature and at least 10 µl the supernatant was plated on
a LB-agar containing petri dish along with 100–300 µl of the
host strain and 3 ml of melted 0.7% soft-agar. The plates were
incubated overnight at +37◦C. If plaques were observed on the
bacterial lawn, a separate plaque was picked and transferred
into 500 µl of LB-broth. A sample from this plaque-stock was
further plated on the same host strain. Plaque-puriﬁcation was
performed three times for all discovered phages in order to isolate
a single homogenous phage from the potentially heterogeneous
phage mix that may have been present in the initial enrichment.
Due to poor isolation success for S. aureus, diﬀerent
modiﬁcations of the above-described method were used for
enriching phages. The volume of the ﬁrst enrichment step as well
as the number of enrichment steps was increased (120 ml sewage
sample + 70 ml L broth + 1 ml host overnight cultures in the
ﬁrst step). Rotation speed during shaken cultivation steps was
varied between 100, 120, 180, or 360 rpm. In addition, samples
from diﬀerent sources were used for phage enrichment (River
in Ljubljana, Slovenia, a water-lock sample from the Helsinki
university hospital and soil samples from a livestock farm). These
samples were not included in analysis of isolation success from
sewage.
Preparation of Phage Stock
Semi-conﬂuent plates (i.e., plates of which about half of the area
is covered by phage induced plaques and the rest is bacterial
lawn) were prepared by plating 100 µl of host strain (300 µl
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TABLE 2 | Probability for discovering a bacteriophage from a sewage sample against different pathogens.
Bacterial pathogen Mean hit %∗ Isolation attempts Number of strains hit
Acinetobacter baumannii 38.9 34 5/9
Enterococcus faecium/faecalis 33.9 27 5/14
Escherichia coli 90.6 35 15/16
Klebsiella pneumoniae 83.3 15 6/6
Pseudomonas aeruginosa 79.4 44 15/17
Salmonella sp. 88.9 11 8/9
Staphylococcus aureus 6.1 117 1/12
∗As calculated over the bacterial strains of the given species.
of Enterococcus strains) and 3 ml of melted soft-agar with
appropriate dilution of the phage stock. Plates were incubated
overnight at +37◦C. The soft-agar layers of semi-conﬂuent
plates were combined with 2.5–5 ml of LB-broth/plate. The
combination was incubated for 4 h at +37◦C, 230 rpm, and
centrifuged at 6000 g for 15 min at +4◦C (Megafuge 1.0R,
Heraeus). If we were unable to get semi-conﬂuent plates, we
used as a combination “over-infected” plates supplied with 100–
700 µl of the overnight-cultivated host strain. The supernatant
was ﬁltered (0.2 µm ﬁlter) and stored at +4◦C.
Cross Infection Tests
All phages were used to cross-infect all diﬀerent bacterial strains
of its original host species (excluding P. aeruginosa phages as
only half of them were used) for preliminary evaluation of their
host range. Cross-infection tests were done by spotting 8 µl of
phage stock dilution (1:10 or 1:100) on 100 µl bacterial overnight
culture in soft-agar (0.7%). Plates were incubated at +37◦C
overnight. Formation of less opaque spots on the bacterial lawn
was scored as a successful infection.
Phage Stock Stability
The titer of each phage stock was determined by standard double
agar overlay method by plating a dilution series (10−2–10−8)
immediately after preparation of the stock. Titer of the stock was
determined again after 1-month storage (+4◦C) to estimate the
stability of the stock in LB-medium.
RESULTS
We evaluated the feasibility for generating a personalized
phage-product on-demand against diﬀerent bacterial pathogens.
We chose bacterial species from seven diﬀerent genuses
that are responsible for the majority of hospital acquired
bacterial infections, namely Escherichia, Salmonella, Klebsiella,
Pseudomonas, Staphylococcus, Enterococcus, and Acinetobacer.
Total of 283 phage isolation attempts were conducted for
83 diﬀerent host strains. Overall 108 bacteriophages were
discovered. All of these viruses were characterized for their
plaque morphology and stability (described individually for each
virus in Supplementary Table S2).
Phages were isolated via three consecutive plaque-picking
steps to avoid mixed-culture stocks. Due to diﬀerent plaque
morphologies and titers, the preparation of phage stocks was
adjusted for each phage. However, no actual optimization of
phage production was carried out. The density of viable phage
particles was measured immediately after the preparation of the
stock (Figure 1). In order to determine their viability for acute
use, the number of viable particles was re-measured 1 month
later (see summary in Table 1). On average, the titers of the
stocks decreased around 0.5 log10 during the 1-month storage
in L-broth in 4◦C. However, for some phages of Enterococcus, the
titers could no longer be resolved. Phage-speciﬁc titers and plaque
morphologies are listed in Supplementary Table S2.
The probability for ﬁnding an infectious bacteriophage from
sewage for diﬀerent host bacterium varied substantially (Table 2).
Namely, phages for only a single S. aureus strain, SA10, were
discovered in total of 117 enrichment attempts (the phages
speciﬁc to the one S. aureus strain were obtained at the same time
and they produced visually identical plaques, thus we selected
only one of these phages for subsequent analyses). Conversely,
almost every isolation attempt yielded a bacteriophage for E. coli,
K. pneumoniae, P. aeruginosa, and Salmonella strains. Phage
isolation for Acinetobacter and Enterococcus had success rates
between 30 and 40%. Given the medical importance of MRSA, we
decided to investigate whether alternative source materials would
be more suitable for discovering phages. We obtained water
samples from a water lock situated in a room used to treat MRSA-
patients in Helsinki University Hospital. Two phages for a single
strain (SA10) were found from these samples. A single MRSA-
speciﬁc bacteriophage was isolated from a set of soil samples
acquired from a livestock farm. Also, a water sample from river
Ljubljana, Slovenia, produced a single bacteriophage for strain
SA10. Yet, we failed to ﬁnd a single phage for any of the ten other
MRSA-strains used in the isolation attempts.
As presented in Figure 2, we studied the host-range of the
obtained phages in order to determine their cross-infectivity and
thus the potential to combine previously isolated phages into
phage-cocktails. Aside from a couple of exceptions, almost all
phages isolated for any given P. aeruginosa strain could also infect
majority of the other strains. However, we neither found any
phages for strain PA15 nor did any of the other phages infect this
strain. In addition, only 4 out of 20 tested Pseudomonas phages
infected strain PA6. Detailed characterization of these particular
strains was beyond the scope of this paper.
Along with Pseudomonas phages, some of the Salmonella
phages had a wide host range. E. coli phages tended to infect more
than one strain, except EC1P1, EC11P2, EC15P2, and EC16P1.
For other bacterial species, isolated phages generally had less
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FIGURE 2 | Cross-infectivity of the isolated bacteriophages. Measurements where less than 105 pfu/ml were used are indicated with an asterisk. Only half of
the isolated Pseudomonas phages were used in the experiments. White background indicates no lysis area, black marks clearly detected lysis area and light gray
indicates very dim lysis area in the spot test. AB, Acinetobacter baumannii; EC, Escherichia coli; EF, Enterococcus faecium or faecalis; KB, Klebsiella pneumoniae;
PA, Pseudomonas aeruginosa; S, Salmonella sp., and SA, Staphylococcus aureus.
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alternative hosts, if any, indicating that a rapid preparation
of a personalized phage-cocktail is likely to require multiple
separate but simultaneous phage enrichments using a single
bacterial strain as a host. Especially, Klebsiella and Enterococcus
phages are very host speciﬁc. Sometimes phage stocks produced
only a dim inhibition area on alternative hosts (presented as
light gray coloring in Figure 2). This suggests that something,
but not necessarily the phage in the prepared stocks was
restricting the growth of the bacterium. Furthermore, phages
isolated for any particular host often had similar infection
patterns. This suggests that additional isolation attempts
using the same isolation source for enrichment may not
be the best choice for improving the host-range of the
cocktail.
DISCUSSION
Due to the enormous variety of bacteriophages in environmental
reservoirs, on-demand isolation of novel phage-antibacterials is
a potential way to generate a personalized medicine for treating
bacterial infections that are resistant to conventional drugs. In
this study, we evaluated the feasibility of isolating phages for such
therapeutic cocktails.
The eﬀorts required to ﬁnd phages diﬀers substantially
between bacterial species. Phages can be readily discovered
for E. coli, K. pneumoniae, P. aeruginosa, and Salmonella
species. Although virus production was neither optimized
nor standardized in this study, phages of these hosts also
readily generated high-density virus stocks (Figure 1). In
contrast, we found it very challenging to isolate phages
against Staphylococcus strains despite of several attempts that
were conducted at diﬀerent times of year and from multiple
sources (sewage, river, hospital water lock, and livestock farm
soil samples). It was also more laborious to isolate phages
for E. faecium and faecalis and A. baumannii, although it
must be noted that we had only handful of these strains
and we performed only few isolation attempts for them.
Nevertheless, based on the results, the on-demand discovery
of phages appears to be feasible for some but not all
bacteria. This highlights the importance of premade wide-
host range cocktails or the existence of other antimicrobial
solutions against species such as S. aureus (such as the one
developed by Kelly et al., 2011). Also, teixobactin, the ﬁrst
new potential antibiotic to be discovered in 30 years is very
eﬀective against bacteria lacking the outer membrane (such
as S. aureus and Enterococcus; Ling et al., 2015). Yet, gram-
negative pathogens with the impermeable outer membrane
(e.g., E. coli, Salmonella, K. pneumonia, and P. aeruginosa)
are inherently resistant to antibiotics like teixobactin, but
contrastingly appear to be suitable targets for obtaining a
cocktail from environmental reservoir (sewage) as needed.
Also, better preservability and wider host-range of these
phages supports the on-demand isolation approach. While
conventional tools for antibiotic development may still remain
relevant, in the face of worsening world-wide antibiotic
resistance crisis we should be actively exploring these promising
alternatives in order to retain the upper hand against all
pathogens.
Generalization of the obtained results must be done while
acknowledging the potential sources of error. First, while
we collected our sewage samples at diﬀerent times (over
the timespan of almost 2 years), only a single wastewater
management plant was used. Although the biological material
in these plants changes constantly, the phage populations
may still be substantially diﬀerent in diﬀerent plants, thus
possibly skewing the chances for ﬁnding phages against certain
species. Moreover, the host ranges of some phages appear
identical, suggesting that the hosts themselves may be genetically
very close to one another. Second, albeit we performed
several hundred isolation attempts, just a few isolations were
performed for any particular strain and thus the achieved
probabilities should be treated as a case study rather than an
exhaustive evaluation. Third, we did not perform an in-detail
characterization for the isolated phages. Such characterization,
at least to some extent, will be necessary during actual
therapy practices (Skurnik et al., 2007; Merabishvili et al., 2009;
Keen, 2012), as bacteriophages are known to carry undesirable
genes coding for toxins and antibiotic resistances (Loc-Carrillo
and Abedon, 2011). However, separating lytic phages from
temperate phages (possibly when accompanied with genome
sequencing and analysis) should be enough and feasible for
the rapid assessment of safety (Chan et al., 2013). Also, phage
stocks have to be puriﬁed from (host-bacterium generated)
endotoxins before therapeutic use (Keen, 2012). These steps
were not performed or their eﬀects on phages evaluated in this
study.
CONCLUSION
The success of on-demand isolation of phages appears to be
critically dependent on the bacterial host. Promisingly, against
pathogens for which conventional antibiotics are becoming the
least useful, such as ESBL E. coli and K. pneumoniae, personalized
phage therapy could be considered as a potential alternative.
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